Nordson (NDSN) Investor Day 2024 summary

Strategic roadmap and growth framework

• Ascend Strategy and NBS Next, launched in 2020, are driving top-tier growth, margin expansion, and operational excellence, focusing on a balanced mix of organic and inorganic expansion over the next five years.

• Portfolio transformation, including targeted M&A and divestitures, has shifted focus to higher-growth, less cyclical end markets, especially medical and advanced technology sectors, with medical market exposure rising from 6% to 27% post-Atrion acquisition.

• NBS Next, a proprietary growth framework, is embedded across all divisions and acquisitions to sustain above-market organic growth, successful integration, and operational improvements.

• Competitive advantages include leadership in niche markets, high recurring revenue, direct-to-customer model, and a culture of innovation.

• Strong free cash flow generation supports both organic investments and strategic capital deployment.

Segment performance and market positioning

• Industrial Precision Solutions delivers $1.5B in annual revenue with 36% EBITDA margins, focusing on automation, sustainability, advanced materials, and global diversification.

• Medical and Fluid Solutions segment, now $850M post-Atrion, achieves 34% EBITDA margin and 8% five-year sales CAGR, driven by aging population, minimally invasive technologies, and premium margins.

• Advanced Technology Solutions has grown to $503M, expanding EBITDA margins by 900 bps, and is positioned to benefit from secular growth in semiconductors and electronics.

• Each segment leverages NBS Next for above-market growth, margin expansion, and operational improvements, with real-world examples of product simplification, lead time reduction, and market share gains.

• End-market exposure is balanced, with no single market over 30% of revenue, and recurring revenues now at 56%.

Financial targets and capital deployment

• 2025–2029 targets: 6%-8% average annual revenue growth and 10%-12% adjusted EPS growth, with EBITDA margins projected at 32%-34%.

• Organic growth expected at 3%-4% per year, with the remainder from disciplined M&A, supported by secular tailwinds in targeted markets.

• EBITDA margin accretion of 100-300 bps anticipated, with ROIC maintained at 12%-14%.

• Cash flow generation through 2029 is projected at ~$4.1B, with 69%-70% allocated to organic growth, dividends, M&A, share repurchases, and debt service, maintaining a leverage ratio of 2-2.5x.

• Ample optional debt capacity and financial flexibility to pursue larger acquisitions if the right opportunities arise.